Event-Driven Stocks

Journey Medical Corp

DERMNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs2 good3 warning2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$61.2M$55.1M$59.7M$71.0M$63.1M$44.5M
Operating income−$8.2M−$13.7M−$2.1M−$27.5M−$34.9M$7.9M
Net income−$11.4M−$14.7M−$3.9M−$29.6M−$44.0M$5.3M
Total assets$94.6M$80.2M$76.8M$105.2M$97.3M$51.9M
Total liabilities$62.7M$60.2M$56.5M$88.2M$55.2M$41.6M
Equity$31.9M$20.1M$20.4M$17.0M$42.0M$10.3M
EPS (diluted)$-0.47$-0.72$-0.21$-1.69$-4.32$0.49
Shares out.24.5M20.4M18.2M17.5M10.2M10.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−13.3%
Net margin
−18.7%
Return on equity
−35.9%
Return on assets
−12.1%
Return on capital (ROCE)
−14.3%
Liabilities / assets
66.3%
Debt / equity
1.97×
Book value / share
$1.30
Revenue growth (YoY)
11.1%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-1.40distress
Accruals / assets
1.1%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
43
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 33Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

2 severe3 warning2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
12 acquisitions0 disposalsnet +1.5M shares · last 12
InsiderDateTypeSharesPrice
Alloush RamseyOfficer — Chief Operating OfficerApr 22, 2026Grant46,863$0.00
Benesch JosephOfficer — CFOApr 22, 2026Grant28,907$0.00
Maraoui ClaudeOfficer — President &amp; CEOApr 22, 2026Grant49,277$0.00
Maraoui ClaudeOfficer — President &amp; CEOAug 25, 2025Option exercise1.3M$0.07
Rosenwald Lindsay A MdDirectorAug 5, 2025Grant50,000$0.00
Smith Justin AdamDirectorAug 5, 2025Grant20,000$0.00
Toledano Miranda JayneDirectorAug 5, 2025Grant20,000$0.00
Pearce Michael CooperDirectorAug 5, 2025Grant20,000$0.00
Herskowitz NeilDirectorAug 5, 2025Grant20,000$0.00
Toledano Miranda JayneDirectorJun 25, 2025Grant7,173$0.00
Rosenwald Lindsay A MdDirectorJun 25, 2025Grant7,173$0.00
Pearce Michael CooperDirectorJun 25, 2025Grant7,173$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20263.5M11.4-5.6%
Apr 30, 20263.7M20.8-1.2%
Apr 15, 20263.7M18.6+7.6%
Mar 31, 20263.5M7.3+31.3%
Mar 13, 20262.6M31.0+3.4%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.